JP2019534247A - ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 - Google Patents

ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 Download PDF

Info

Publication number
JP2019534247A
JP2019534247A JP2019512681A JP2019512681A JP2019534247A JP 2019534247 A JP2019534247 A JP 2019534247A JP 2019512681 A JP2019512681 A JP 2019512681A JP 2019512681 A JP2019512681 A JP 2019512681A JP 2019534247 A JP2019534247 A JP 2019534247A
Authority
JP
Japan
Prior art keywords
nrp
nnif
seq
net
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019512681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534247A5 (de
Inventor
クリスチャン コン ヨースト
クリスチャン コン ヨースト
ガイ エイ ツィマーマン
ガイ エイ ツィマーマン
アンドリュー エス ウェイリッチ
アンドリュー エス ウェイリッチ
ジョシュア シフマン
ジョシュア シフマン
Original Assignee
ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション
ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション, ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション filed Critical ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション
Publication of JP2019534247A publication Critical patent/JP2019534247A/ja
Publication of JP2019534247A5 publication Critical patent/JP2019534247A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019512681A 2016-09-02 2017-09-05 ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 Pending JP2019534247A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US62/383,243 2016-09-02
US201762492019P 2017-04-28 2017-04-28
US62/492,019 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (2)

Publication Number Publication Date
JP2019534247A true JP2019534247A (ja) 2019-11-28
JP2019534247A5 JP2019534247A5 (de) 2020-10-15

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512681A Pending JP2019534247A (ja) 2016-09-02 2017-09-05 ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法

Country Status (13)

Country Link
US (1) US10857201B2 (de)
EP (1) EP3506924A4 (de)
JP (1) JP2019534247A (de)
KR (1) KR20190045271A (de)
CN (1) CN109937047A (de)
AU (1) AU2017321965A1 (de)
BR (1) BR112019004299A2 (de)
CA (1) CA3035770A1 (de)
MX (1) MX2019002479A (de)
RU (1) RU2019109049A (de)
SG (1) SG11201901830UA (de)
WO (1) WO2018045371A2 (de)
ZA (1) ZA201901942B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods
EP4146237A1 (de) * 2020-05-04 2023-03-15 University of Utah Immunthrombose bei covid-19-akust-respiratorischem stresssyndrom
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194365A1 (en) * 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194365A1 (en) * 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COOLS-LARTIGUE, J. ET AL.: "Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 8, JPN6021030409, 1 August 2013 (2013-08-01), pages 3446 - 3458, XP055684654, ISSN: 0004567118, DOI: 10.1172/JCI67484 *

Also Published As

Publication number Publication date
CN109937047A (zh) 2019-06-25
RU2019109049A3 (de) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (de) 2020-05-20
EP3506924A2 (de) 2019-07-10
MX2019002479A (es) 2019-09-19
US20190201487A1 (en) 2019-07-04
WO2018045371A2 (en) 2018-03-08
WO2018045371A3 (en) 2018-04-12
RU2019109049A (ru) 2020-10-05
CA3035770A1 (en) 2018-03-08
BR112019004299A2 (pt) 2019-05-28
AU2017321965A1 (en) 2019-04-04
SG11201901830UA (en) 2019-03-28
KR20190045271A (ko) 2019-05-02
ZA201901942B (en) 2020-10-28

Similar Documents

Publication Publication Date Title
Yost et al. Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation
Deng et al. Citrullinated histone H3 as a therapeutic target for endotoxic shock in mice
US10646556B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
Jiang et al. Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial infarction
Zhou et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury
Lehrer Primate defensins
Shirasuna et al. Nanosilica-induced placental inflammation and pregnancy complications: Different roles of the inflammasome components NLRP3 and ASC
EP2209485B1 (de) Extrazelluläre histone als biomarker zur prognose und zielmoleküle zur behandlung
AU4393600A (en) Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US8304389B2 (en) Methods of inhibiting cell death or inflammation in a mammal by administering a BCL protein
EP3017824B1 (de) Inhibitor der bildung von extrazellulären fallen in leukozyten
US20110229435A1 (en) Expression and purification of hip/pap and uses therefor
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
US11324801B2 (en) NNIF and nNIF-related peptides and related methods
EP3205347A1 (de) Hemmer zur herstellung einer extrazellulären falle für weisse blutzellen
Olonisakin Stressed Erythrophagocytosis as a Modifier of the Innate Immune Response to Klebsiella pneumoniae
US20190092814A1 (en) Peptide
WO2024097571A1 (en) Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
Alteber The anti-inflammatory IFITM genes act as tumor suppressors
McNamee et al. Enhancing central noradrenergic tone promotes IL-10 production and signalling in the CNS via ß-adrenoceptor activation (Abstract No. 20)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220627